With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had come to rely on compounded versions is increasingly uncertain.

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers.

Former FDA Commissioner David Kessler shared his experience with GLP-1 weight loss drugs on "CBS Mornings Plus."

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it may be possible to improve the efficacy of semaglutide and other GLP-1 acting drugs, which can have side effects including nausea, diarrhoea, vomiting, constipation, stomach pain, headache, and tiredness, amongst others.

Weight-loss injections, or GLP-1 receptor agonists, could nearly halve the risk of obesity-related cancers, a new study finds amid rising global obesity rates.

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the journal eClinicalMedicine finds that first-generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic disease in the United States.